CAC
CBAY

Cowen and Company’s Cymabay Therapeutics CBAY Stock Holding History

Cowen and Company’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-75,000
Closed -$124K – 770
2021
Q4 		$124K Buy
75,000
+3,200
+4% +$12.1K 0.01% 344
2021
Q3 		$97K Hold
71,800
– – ﹤0.01% 322
2021
Q2 		$99K Buy
+71,800
New +$318K 0.01% 344
2020
Q3 		– Sell
-40,000
Closed -$25K – 537
2020
Q2 		$25K Buy
+40,000
New +$115K ﹤0.01% 330

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Cowen and Company's CBAY Position: Q1 2022 in Review

Cowen and Company sold out of Cymabay Therapeutics (CBAY) in Q1 2022, closing a stake of 65,600 shares — an estimated $222K sold.

Cowen and Company first reported a position in CBAY in Q2 2020 and held it in 4 quarters. The position peaked at $262K in Q3 2021. 118 funds tracked by Wall St. Rank hold CBAY as of Q1 2022.

  • Cowen and Company reported no remaining Cymabay Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Cowen and Company sold 65,600 Cymabay Therapeutics shares in Q1 2022, an estimated $222K.
  • Cowen and Company first reported a position in Cymabay Therapeutics in Q2 2020 and held it in 4 quarters.
  • Cowen and Company's Cymabay Therapeutics position peaked at $262K in Q3 2021.
  • 118 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2022.

Based on Cowen and Company's 13F filing for Q1 2022, filed 16 May 2022.